NCT05847218 is a Phase 1 clinical trial of RHN-001 (one tablet 750mg) in Safety, sponsored by RH Nanopharmaceuticals.

Who is sponsoring NCT05847218?

NCT05847218 is sponsored by RH Nanopharmaceuticals.

What drugs are being tested in NCT05847218?

Interventions in NCT05847218: RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets).

What condition does NCT05847218 study?

NCT05847218 studies Safety, Tolerability, Pharmacokinetics.

Is NCT05847218 still recruiting?

NCT05847218 is currently completed. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT05847218

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers

Completed Phase 1 Last updated 6 May 2023

What this trial tests

Phase 1 trial testing RHN-001 (one tablet 750mg) in Safety in 64 participants. Completed in 19 March 2023.

Timeline

9 March 2023

Primary endpoint
19 March 2023

19 March 2023

Quick facts

Lead sponsor	RH Nanopharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	other
Enrollment	64
Start date	9 March 2023
Primary completion	19 March 2023
Estimated completion	19 March 2023
Sites	1 location across Pakistan

Drugs / interventions tested

RHN-001 (one tablet 750mg) — full drug profile →
RHN-001 (750mg * 2 Tablets) — full drug profile →

Conditions studied

Safety — all drugs for Safety →
Tolerability — all drugs for Tolerability →
Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

RH Nanopharmaceuticals — full company profile →

Who can join

Adults 18 to 55, any sex, with Safety or Tolerability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical Trial is to assess the safety, tolerability and Pharmacokinetic profile of 750 mg single oral dose of RHN-001 and 1500 mg of RHN-001 administered orally in fasted and fed conditions in healthy adult volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Safety

Currently open trials in the same condition.

NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05847218 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RH Nanopharmaceuticals
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05847218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing